KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash & Equivalents (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Cash & Equivalents data on record, last reported at $121.2 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 69.36% year-over-year to $121.2 million; the TTM value through Dec 2025 reached $121.2 million, up 69.36%, while the annual FY2025 figure was $121.2 million, 69.36% up from the prior year.
  • Cash & Equivalents reached $121.2 million in Q4 2025 per AQST's latest filing, down from $129.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $129.1 million in Q3 2025 and bottomed at $14.7 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $50.6 million, with a median of $29.6 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: crashed 48.31% in 2022, then soared 300.56% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $28.0 million in 2021, then decreased by 2.68% to $27.3 million in 2022, then dropped by 12.47% to $23.9 million in 2023, then surged by 199.71% to $71.5 million in 2024, then surged by 69.36% to $121.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $121.2 million in Q4 2025, $129.1 million in Q3 2025, and $60.5 million in Q2 2025.